Sage Journals: Discover world-class research

Abstract

Purpose:

Patients with hematological malignancies (HM) have more unpredictable disease trajectories compared to patients with advanced solid tumors (STs) and miss opportunities for a palliative care approach. They often undergo intensive disease-directed treatments until the end of life with frequent emergency department (ED) visits and in-hospital deaths. Insight into end-of-life trajectories and quality of end-of-life care can support arranging appropriate care according to patients’ wishes.

Method:

Mortality follow-back study to compare of end-of-life trajectories of HM and ST patients who died <3 months after their ED visit. Five indicators based on Earle et al. for quality of end-of-life care were assessed: intensive anticancer treatment <3 months, ED visits <6 months, in-hospital death, death in the intensive care unit (ICU), and in-hospice death.

Results:

We included 78 HM patients and 420 ST patients, with a median age of 63 years; 35% had Eastern Cooperative Oncology Group performance status 3-4. At the ED, common symptoms were dyspnea (22%), pain (18%), and fever (11%). After ED visit, 91% of HM patients versus 76% of ST patients were hospitalized (P = .001). Median survival was 17 days (95% confidence interval [CI]: 15-19): 15 days in HM patients (95% CI: 10-20) versus 18 days in ST patients (95% CI: 15-21), P = .028. Compared to ST patients, HM patients more often died in hospital (68% vs 30%, P < .0001) and in the ICU or ED (30% vs 3%, P < .0001).

Conclusion:

Because end-of-life care is more aggressive in HM patients compared to ST patients, a proactive integrated care approach with early start of palliative care alongside curative care is warranted. Timely discussions with patients and family about advance care planning and end-of-life choices can avoid inappropriate care at the end of life.

Keywords

hematological malignancy cancer palliative care supportive care end-of-life care emergency department

Introduction

The disease trajectories of patients with a hematological malignancy (HM) are diverse, from diseases with an acute manifestation and poor survival to those with a chronic nature. Treatments for HMs, even in patients with a poor clinical condition, are often intensive and are associated with a high risk of severe toxicity (such as graft-versus-host disease), infection, and even death.¹ Because disease trajectories of patients with HM are unpredictable and life threatening, recognition of those who could benefit from a palliative care approach is complicated.^2

-6 As a consequence, patients with HM are seldom referred to palliative care consultation teams (PCCTs) or hospices, and if they are referred, they often die within days or weeks.^2,7,8 It is known that palliative care needs of patients with HM are often unmet.⁹ According to the definition of the World Health Organization, the aim of a palliative care approach is to improve quality of life of both patients and family; in addition, it can concur with curative systemic treatment along the disease trajectory.¹⁰ This approach includes conversations about the end of life, supportive care, symptom management, and psychosocial support.⁹ Insight into the end-of-life trajectory of patients with HM may help identifying cues for initiation of a palliative care approach.

With the occurrence of disease progression or metastases, the palliative phase in patients with a solid tumor (ST) is easier to identify.^6,7,11 According to Murray, their physical decline is stable and predictable until a steep and short period of decline before death. During the stable phase, health-care providers can proactively assess and support palliative care needs at the end of life.¹² A palliative care approach has been shown to be effective in a various populations of patients with ST in improving quality of life, symptom burden, and even survival.^13
-15 In patients with HM, palliative care can improve the quality of life after hematopoietic stem cell transplantation already after 2 weeks, as a randomized controlled study by El-Jawahri et al. showed.¹⁶ However, literature indicates that patients with HM need a different proactive approach for early palliative care than the disease trajectory of patients with advanced ST. Conceptual models of integrated palliative care for patients with HM depict palliative care as concurrent with curative care to aim for both cure and care.^17
-19 So-called trigger events can help identifying patients with HM with palliative care needs to arrange appropriate care.²⁰ An ED visit is shown to be a potential trigger.²¹

Many patients with HM are urged to visit the emergency department (ED) with uncontrollable symptoms or a high symptom burden at home. Consecutively, they are often admitted to the hospital or even to an intensive care unit (ICU), where many of them die.^2,22,23 These situations can diminish the quality of the end of life of patients with HM and their families.²⁴ To measure the quality of end-of-life care provided to patients with incurable diseases, Earle et al. constructed the following indicators: receiving chemotherapy in the last 14 days of life, starting a new chemotherapy in the last 30 days of life, >1 ED visit in the last month of life; >1 hospitalization in the last month of life; ICU admission in the last month of life; death in an acute care hospital; lack of hospice admission; and admission to hospice <3 days before death.^24,25

The primary objective of this study was to provide insight into the end-of-life trajectory of patients with HM visiting the ED during the last 3 months of life and to compare them with patients with ST. Secondary objective was to compare the quality of end-of-life care in patients with HM and ST.

Patients and Methods

Setting

This mortality follow-back study was conducted at Leiden University Medical Center (LUMC) in Leiden, the Netherlands. The LUMC’s ED is open 24 hours a day, 7 days a week. On average, 80 patients visit the ED every day and about 30 000 patients are evaluated every year. Since 2011, LUMC has a PCCT, which is available to all departments of our center for consultation after patients are referred by their health care provider. This study was part of a larger study on end-of-life trajectories of all patients visiting the ED between 2011 and 2013, approved by LUMC’s Committee of Medical Ethics on May 27, 2013. Written consent was not required according to Dutch Law (WGBO, article 458) and European Law (General Data Protection Regulation).

Patients

All adult patients with HM who died within 3 months after their last ED visit were included. They were compared to patients with ST having advanced cancer, which was defined as not having any curative options or receiving anticancer treatment not aimed at curation. Detailed analysis of patients with ST is published elsewhere.²⁶ The period of 3 months was chosen because in the Netherlands, an estimated life expectancy of <3 months justifies referral to intensive palliative care at home, in nursing homes, and in hospices. Data collection occurred from May 2011 to January 2013.

Data Collection

For transparent and solid data collection, a code book was designed by 2 members of our PCCT, which contained inclusion and exclusion criteria and description and coding of all variables.²⁷ Characteristics of disease, referral, ED visit, and follow-up from ED arrival until death were extracted from electronic patient records (EPRs) of eligible patients by 4 trained research assistants. One expert of the PCCT checked for interrater agreement. Electronic patient records were searched for any correspondence with general practitioners (GPs) or PCCT consultations during the 3 months before the ED visit and proactive symptom management plans in files or letters up to 6 weeks before the ED visit. Limitations on life-sustaining treatments (LSTs) were orders on no resuscitation, no ventilation and no admission to the ICU. Discussions on LST did not occur routinely and notes about LSTs were collected by the research assistants. Arrival at the hospital within office hours was defined as from Monday to Friday between 8 am and 6 pm. Performance status was scored using the scale.²⁸ The main symptom was defined as the referring symptom reported by the attending physician and is part of the structure of reporting in the EPR. This symptom was considered “new” if it was not mentioned in the EPR 3 months before the ED visit; it was considered “acute” if the onset of the symptom was <24 hours. The clinical diagnosis was defined as the conclusion reported by the attending physician in the EPR. Date and place of death were obtained from EPRs. Cause of death in patients with HM was discussed between one expert of the PCCT (E.J.M.d.N.) and a hematologist (C.S.O.) until agreement was reached. Cues for proactive care were communication about the patient’s condition between a health-care provider or PCCT of the hospital and the patient’s GP via a letter, telephone, or transfer; proactive care plans (care plan for anticipation of symptoms, care plans informing the GP, care plans written by the PCCT, PCCT referrals); and limitations on LSTs before the current ED visit. Quality of end-of-life care was assessed using indicators for proactive end-of-life care and indicators of Earle et al: intensive anticancer treatment in the previous 3 months before the ED visit (intensive anticancer treatments include chemotherapy, targeted therapy, stem cell transplantation, and surgery), the number of ED visits in the 6 months before the current ED visit, in-hospital death, death in an acute hospital department (the ED or the ICU), and death in a hospice (as a positive measure).²⁴

Statistics

Characteristics of patients, referrals, ED visits, and follow-up were analyzed using descriptive statistics. To test differences between patients with HM and ST, we performed χ² tests for nominal variables, Mann-Whitney U tests for non-normally distributed continuous or ordinal variables, and Fisher-Freeman-Halton tests for variables with 3 or more categories. Kaplan-Meier’s methodology was used to estimate survival from the ED visit, and survival between patients with HM and ST was tested using a log-rank test. Complete case analyses were performed, using SPSS 23.0 software, and a 2-sided P value <.05 was considered statistically significant.

Results

Patient and Disease Characteristics

Seventy-eight patients with HM and 420 patients with ST died within 3 months after their ED visit (Table 1); more men were in the HM group (67.9% vs 54.5% of patients with ST, P = .026); median age was 63 years (range: 22-94 years). Eastern Cooperative Oncology Group performance score did not differ between patients with HM and ST. Acute myeloid leukemia and multiple myeloma were the most common HM types (26% and 17%, respectively); most STs were located in the digestive tract (27.6%) and in the lung (16.0%; Online Appendix 1). Before the ED visit, limitations on LSTs were discussed with 171 patients (34.3%): with 13 (16.7%) patients with HM and 158 (37.6%) patients with ST (P < .0001). Four (5.1%) patients with HM and 142 patients with ST (33.8%) had documented limitations; “no limitations” were documented in 9 (11.5%) patients with HM and 16 (3.8%) patients with ST (P < .0001). Up to 3 months before the ED visit, the PCCT was consulted in 27 patients (1 patient with HM and 26 patients with ST, P = .10). Communication via letters, telephone, and transfers between medical specialists and the patient’s GP had occurred in 67 (85.9%) patients with HM and 332 (79.0%) patients with ST (P = .15). Proactive care plans were documented for 13 (16.7%) patients with HM and 66 (15.7%) patients with ST (P = .83).

Table 1.

Characteristics of 78 Patients With a Hematological Malignancy and 420 Patients With a Solid Tumor Visiting the Emergency Department.

Characteristics	Total (N = 498)	HM Patients (n = 78)	ST Patients (n = 420)	P Value
Characteristics	n (%)	n (%)	n (%)	P Value
Male	282 (56.6)	53 (67.9)	229 (54.5)	.026
Age in years, median (range)	63 (22-94)	61 (27-94)	61 (22-92)	.147
Disease-modifying treatment in the past 3 months^a
Chemotherapy	202 (40.6)	34 (43.4)	168 (40.0)	.554
Radiotherapy	118 (23.7)	14 (17.9)	104 (24.8)	.182
Targeted therapy/immunotherapy	96 (19.3)	21 (26.9)	75 (17.9)	.065
Stem-cell transplantation	10 (2.0)	9 (11.5)	1 (0.2)	<.0001
None	125 (25.1)	14 (17.9)	111 (26.4)	.102
Limitations on LSTs^b				<.0001
Discussed, no documented limitations	25 (5.0)	9 (11.5)	16 (3.8)
Discussed, documented limitations	146 (29.3)	4 (5.1)	142 (33.8)
Not discussed	327 (65.7)	65 (83.3)	262 (62.4)
PCCT consulted during last 3 months	27 (5.4)	1 (1.3)	26 (6.2)	.100
Proactive symptom management plan in the prior 6 weeks	62 (12.4)	11 (14.1)	51 (12.1)	.612
Number of ED visits during the last 6 months, median (range)	1 (0-9)	1 (0-9)	1 (0-7)	.147
Patient had a family caregiver				.608
Yes	433 (86.9)	67 (85.9)	366 (87.1)
No	31 (6.2)	6 (7.7)	25 (6.0)
Unknown	34 (6.8)	5 (6.4)	29 (6.9)
Patient had homecare before the ED visit				.462
Yes	110 (22.1)	19 (24.4)	91 (21.7)
No	280 (56.2)	44 (56.4)	236 (56.2)
Unknown	108 (21.7)	15 (19.2)	93 (22.1)
Living situation				.120
Alone	90 (18.1)	10 (12.8)	80 (19.0)
With someone	369 (74.1)	65 (83.3)	304 (72.4)
Unknown	39 (7.8)	3 (3.8)	36 (8.6)
Housing				.075
Home	447 (89.8)	66 (84.6)	381 (90.7)
Residential home	9 (1.8)	2 (2.6)	7 (1.7)
Nursing home	18 (3.6)	6 (7.7)	12 (2.9)
Hospice	6 (1.2)	1 (1.3)	5 (1.2)
Other	5 (1.0)	2 (2.6)	3 (0.7)
Unknown	13 (2.6)	1 (1.2)	12 (2.9)
WHO performance score				.078
0-2	90 (18.1)	17 (21.8)	73 (17.4)
3-4	173 (34.7)	50 (64.1)	123 (29.3)
Unknown	235 (47.2)	11 (14.1)	224 (53.3)

Abbreviations: ED, emergency department; HM, hematological malignancy; LSTs, life-sustaining treatments; PCCT, palliative care consultation team; ST: solid tumor; WHO, World Health Organization.

^a Numbers may exceed 100% because patients may have received multiple disease-modifying therapies in the past.

^b Limitations on LSTs were defined as orders on no resuscitation, no ventilation, and no admission to the intensive care unit.

Referral Characteristics

Patients or their family initiated the ED visit in 37.3% (Table 2). Two hundred fifty-eight (51.8%) came outside office hours. Most common main symptoms were dyspnea (22.1%), pain (17.5%) and fever (11.2%). Patients with HM more often presented with fever (23.1% vs 9.0% of the patients with ST, P = .001); patients with ST more often presented with nausea or vomiting (9.3% vs 2.6% of the patients with HM). Patients had a median of 2 symptoms.

Table 2.

Emergency Department-Referral Characteristics of 78 Patients With a Hematological Malignancy and 420 Patients With a Solid Tumor.

ED Referral	Total (N = 498)	HM Patients (n = 78)	ST Patients (n = 420)	P Value
ED Referral	n (%)	n (%)	n (%)	P Value
Referrer				.420
GP or elderly care physician	189 (38.0)	25 (32.1)	164 (39.0)
Medical specialist	123 (24.7)	23 (29.5)	100 (23.8)
Patient or informal caregiver	186 (37.3)	30 (38.5)	156 (37.1)
Referral outside office hours	258 (51.8)	40 (51.3)	218 (51.9)	.919
Main symptom
Dyspnea	110 (22.1)	22 (28.2)	88 (21.0)	.166
Pain	87 (17.5)	9 (11.5)	78 (18.6)	.117
Fever	56 (11.2)	18 (23.1)	38 (9.0)	.001
Neurologic deterioration^a	41 (8.4)	8 (10.3)	33 (7.9)	.491
Nausea or vomiting	41 (8.2)	2 (2.6)	39 (9.3)	.025
Weakness or loss of strength	25 (5.0)	6 (7.7)	19 (4.5)	.256
Bleeding	23 (4.6)	3 (3.8)	20 (4.8)	>.999
Obstipation or diarrhea	17 (3.4)	1 (1.3)	16 (3.8)	.493
Fatigue	12 (2.4)	4 (5.1)	8 (1.9)	.102
Difficulty swallowing or passage problems	9 (1.8)	0 (0.0)	9 (2.1)	.367
Seizure	9 (1.8)	1 (1.3)	8 (1.9)	>.999
Edema	8 (1.6)	0 (0.0)	8 (1.9)	.617
Ascites	7 (1.4)	0 (0.0)	7 (1.7)	.603
Other	53 (10.6)	4 (5.1)	49 (11.7)	.062
Admission for
New problem^b	254 (51.0)	35 (44.9)	219 (52.1)	.238
Acute problem^c	179 (35.9)	24 (30.8)	155 (36.9)	.295
Number of symptoms, median (range)	2 (0-8)	2 (0-8)	2 (0-7)	.055

Abbreviations: ED, emergency department; GP, general practitioner; HM, hematological malignancy; ST, solid tumor.

^a Confusion, drowsiness, reduced consciousness.

^b Not reported in the patient records in the last 3 months.

^c Onset within the last 24 hours.

Visit and Follow-Up Characteristics

Patients underwent diagnostic imaging in 64.1% and laboratory tests in 84.1% (Table 3). Most patients were diagnosed with infection or fever (24.5%), bronchopulmonary insufficiency (14.3%), or renal insufficiency (11.8%). In patients with HM, treatment for their main symptoms was initiated at the ED more often than in patients with ST (69.2% vs 54.8%, P = .010). After their ED visit, more patients with HM were hospitalized than in patients with ST (91.0% vs 76.0%, P = .001). The ED visit triggered discussions about LSTs in both patients with HM and ST. After the ED visit, LSTs were documented for 41 (52.6%) patients with HM and 307 (73.1%) patients with ST (P < .0001). Among these patients, 39 (95.1%) patients with HM and 297 (96.7%) patients with ST had limitations on LSTs (P = .64). Median survival from the ED visit was 17 days (95% confidence interval: 15-19) and was significantly shorter in patients with HM (15 days vs 18 days, P = .028). In-hospital death occurred in 67.9% of the patients with HM versus 29.5% of the patients with ST; patients with HM died at home in 15.4% versus 38.3% of the patients with ST (P < .0001). In patients with HM, causes of death were disease progression (46.2%), treatment toxicity (39.7%), or both (9.0%).

Table 3.

Emergency Department Visit and Follow-Up Characteristics of 78 Patients With a Hematological Malignancy and 420 Patients With a Solid Tumor.

ED Visit	Total (N = 498)	HM Patients (n = 78)	ST Patients (n = 420)	P Value
ED Visit	n (%)	n (%)	n (%)	P Value
Diagnostic imaging	319 (64.1)	53 (67.9)	266 (63.3)	.326
Laboratory tests	419 (84.1)	69 (88.5)	350 (83.3)	.204
Clinical diagnosis
Infection or fever	122 (24.5)	36 (46.2)	86 (20.5)	<.0001
Bronchopulmonary insufficiency	71 (14.3)	17 (21.8)	54 (12.9)	.051
Renal insufficiency or hydronephrosis	59 (11.8)	12 (15.4)	47 (11.2)	.308
Cachexia	44 (8.8)	4 (5.1)	40 (9.5)	.177
Pleural effusion	36 (7.2)	5 (6.4)	31 (7.4)	.750
Ascites	35 (7.0)	1 (1.3)	34 (8.1)	.010
Bleeding	33 (6.6)	3 (3.8)	30 (7.1)	.250
Jaundice	24 (4.8)	1 (1.3)	23 (5.5)	.151
Neuropathy or plexopathy	20 (4.0)	3 (3.8)	17 (4.0)	>.999
Ileus or passage disturbances	18 (3.6)	0 (0.0)	18 (4.3)	.091
Urine retention	14 (2.8)	1 (1.3)	13 (3.1)	.707
Seizure	14 (2.8)	1 (1.3)	13 (3.1)	.707
Fracture	10 (2.0)	0 (0.0)	10 (2.4)	.375
Deep venous thrombosis	8 (1.6)	1 (1.3)	7 (1.7)	>.999
Coma	8 (1.6)	0 (0.0)	8 (1.9)	.617
Delirium	8 (1.6)	2 (2.6)	6 (1.4)	.365
Pulmonary embolism	8 (1.6)	1 (1.3)	8 (1.9)	.617
Spinal cord compression	5 (1.0)	0 (0.0)	5 (1.2)	>.999
Treatment for main symptom initiated at ED	284 (57.0)	54 (69.2)	230 (54.8)	.010
Time spent at ED in hours:minutes, median (range)	3:32 (0:12-18:01)	3:37 (0:42-12:12)	3:39 (0:12-18:01)	.708
Follow-up
ED visit followed by hospital admission	390 (78.3)	71 (91.0)	319 (76.0)	.001
Observed survival in days, median (95% CI)	17 (15-19)	15 (10-20)	18 (15-21)	.028
Place of death				<.0001
Clinical ward	143 (28.7)	30 (38.5)	113 (26.9)
ICU or ED	34 (6.8)	23 (29.5)	11 (2.6)
Home	173 (34.7)	12 (15.4)	161 (38.3)
Nursing or residential home	12 (2.4)	3 (3.8)	9 (2.1)
Hospice	47 (9.4)	2 (2.6)	45 (10.7)
Unknown	89 (17.9)	8 (10.3)	81 (19.3)

Abbreviations: CI, confidence interval; ED, emergency department; HM, hematological malignancy; ICU, intensive care unit; ST, solid tumor.

Quality of End-of-Life Care

Quality of end-of-life care in patients with HM and ST is shown in Table 4. Intensive anticancer treatment was administered to 375 (72.4%) of all patients up to 6 months before the ED visit, to 75.6% of the patients with HM versus 71.8% of the patients with ST, P = .48. Patients with HM died more often in hospital compared to patients with ST (67.9% vs 29.5%, P < .0001), in an acute hospital setting (29.5% vs 2.7%, P < .0001), and less often in a hospice (2.6% vs 10.5%, P = .011).

Table 4.

Comparison of Indicators of Quality of End-of-Life Care Between 78 Patients With a Hematological Malignancy and 420 Patients With a Solid Tumor.

Indicators of Quality of End-Of-Life Care	Total (N = 498)	HM Patients (n = 78)	ST Patients (n = 420)	P Value
Indicators of Quality of End-Of-Life Care	n (%)	n (%)	n (%)	P Value
Intensive anticancer treatment^a	375 (72.4)	59 (75.6)	316 (71.8)	.48
Number of ED visits^b, median (range)	1.00 (0-9)	1.00 (0-9)	1.00 (0-7)	.12
In-hospital death	183 (35.3)	53 (67.9)	130 (29.5)	<.0001
Death in an acute hospital setting^c	35 (6.8)	23 (29.5)	12 (2.7)	<.0001
Death in hospice	48 (9.2)	2 (2.6)	46 (10.5)	.011

Abbreviations: ED, emergency department; HM, hematological malignancy; ICU, intensive care unit; ST, solid tumor.

^a Number of intensive anticancer treatments received in the 3 months before ED visit. Intensive anticancer treatments included chemotherapy, targeted therapy, stem cell transplantation, surgery, radiotherapy, hormonal therapy, nuclear therapy.

^b Number of ED visits in 6 months before current ED visit.

^c Acute hospital settings included the ED and the ICU.

Discussion

This study gives insight into the disease trajectory of patients with HM and into the differences compared to the disease trajectory of patients with an ST visiting the ED in the last 3 months of their lives. Limitations on LSTs were often not discussed in patients with HM before their ED visit, and if these were discussed, patients often had no limitations on LSTs. End-of-life care was considerably more aggressive in patients with HM compared to patients with ST. Patients with HM had a worse survival than patients with ST and more often died in-hospital and in the ICU and seldom in a hospice.

Our results implicate that end-of-life care is aggressive in patients with HM: they scored poorly on 5 of the indicators of quality of end-of-life care by Earle.²⁴ Our findings are in accordance with international literature reporting that patients with HM receive intensive treatments until death. In a study by Hui et al., patients with HM received significantly more chemotherapy (21%) and targeted therapy (17%) than patients with ST (6% and 5%, respectively).² Other studies report that patients with HM often received granulocyte-colony stimulating factor, blood transfusions, and antibiotics and underwent diagnostic imaging, blood sampling, endoscopy, and bone marrow examination in the last 7 days of life.^23,29 A French study in patients who died of metastatic lung cancer showed that end-of-life care was less aggressive the earlier palliative care needs were reported in their EPRs: patients sooner stopped with anticancer treatment and they underwent less often invasive ventilation.³⁰ In patients with pancreatic cancer in the last 30 days of life who were referred to a palliative care service, those with an early referral to a palliative care team visited the ED less often and were less often hospitalized.³¹ It thus seems that when palliative care is integrated into oncology care, patients with ST are at a lower risk of aggressive end-of-life care. In our study, limitations on LSTs were seldom discussed with patients with HM, and remarkably, if it was discussed, it was often explicitly stated in their EPRs that there were no limitations on LSTs. A recent integrative systematic review provided more insight into the aspects of this “curative mind-set”: hematologists feel uncomfortable with hospice referrals and discussing approaching death with patients and family; disease progression is considered as personal failure; and they are concerned that mentioning palliative care early in the disease trajectory might scare patients and their relatives.⁶ A qualitative study by Prod’homme et al. showed that end-of-life discussions are avoided by hematologists as long as cure is possible; these discussions are perceived to damage the doctor–patient relationship, especially when the patient’s prognosis is uncertain.³² In addition, hematologists interpret palliative care more often as end-of-life care than medical oncologists do and are less used to involve a palliative care specialist than medical oncologists.³³ It is known that if patients with HM are referred to palliative care, it generally occurs very late in their disease trajectory.^3,7,11 Although a curative care approach toward patients with HM could be appropriate, the way it is currently practiced discourages timely initiation of a palliative care approach and conversations about the end of life. El-Jawahri et al. reported that 27% of the hospital admissions in acute myeoloid leukemia patients could have been avoided.³⁴ Reasons were: being discharged too soon after the previous admission, visits for problems that would have been manageable at home, and the lack of timely outpatient follow-up appointments. These reasons are starting points for initiating a palliative care approach to avoid possible aggressive and harmful treatments in vulnerable patients.

Our study suggests that in many patients the ED visit marked deterioration and a transition in disease trajectory and often even the start of the dying phase. After the ED visit or following hospital admission, limitations on LSTs were discussed and documented in 73% of the patients with ST and 53% of the patients with HM. Although efforts were made to discuss these LSTs, still 36% of the patients with HM were subsequently transferred to the ICU. This is in line with literature demonstrating that patients with HM are frequently and more often admitted to ICUs than patients with ST (39% and 8%, respectively).² Failure to recognize patients in the end-of-life phase makes them at risk of receiving aggressive treatments in the hospital and may even result in death: in our study, 33% of the patients with HM died in the ICU, compared to 4% of the patients with ST (P < .0001).² Sixty-nine percent of our patients with HM died in the hospital and 40% died as a result of treatment toxicity. Howell et al. showed that, compared to patients with ST, patients with HM had a twice higher risk to die in the hospital.²² Our findings confirm that patients with HM have unpredictable disease trajectories that can suddenly change from curative to dying: most of our patients died shortly after the ED visit with a median survival of only 15 days. Reasons for difficulties to predict survival and to recognize the transition to the end-of-life trajectory are possibly reversible conditions such as infections, increasing availability of systemic therapies that stimulate continuance of active treatment and increase the risk of lethal complications.^1,35 Long-lasting physician–patient relationships are also known to hamper accurate recognition of deterioration.⁶ The combination of these factors makes it difficult for physicians to recognize approaching death in patients with HM and to timely prepare them for their approaching death.

A Proactive Integrated Care Approach

We advocate, as Zimmermann, Bruera, LeBlanc, El-Jawahri, Chung, and Button do, the use of an integrated care approach with 2 concurrent tracks: a curative approach and palliative care approach (Figure 1).^{16

-19,36,37} Integrated care should be initiated early in the disease trajectory if the disease is potentially life threatening (which can be at diagnosis). The first track consists of conventional disease treatment aimed at cure. The second track consists of supportive care following the 4-dimensional principles of palliative care: physical, psychological, social, and spiritual. Importantly, the second track also includes discussions about future problems, treatment choices, hospital admissions, LSTs, and place of death. The palliative care approach has shown to benefit symptom control³⁷ and quality of life,³⁸ to decrease ED visits, hospital and ICU admissions and in-hospital deaths,^39,40 and might even prolong survival.⁴¹ In the integrated care approach, multidisciplinary discussions and communication across specializations within and outside the medical field are crucial to satisfy care needs. The randomized clinical trial by El-Jawahri et al. demonstrated that inpatient palliative care improved the quality of life of patients with HM already within 2 weeks after hematopoietic stem cell transplantation had taken place.¹⁶

Figure 1.

A proactive integrated care approach for patients with a hematological malignancy: a curative and a supportive track.

Our pragmatic study provides insight into the care for patients with HM visiting the ED in their end-of-life trajectory and compared it with the disease trajectory of patients with ST. The inclusion of only those patients who died within 3 months after the ED visit is inherent to the mortality follow-back design of this study, but it has introduced selection bias. Although data were collected from 2011 to 2013, they are still relevant since new life-prolonging systemic treatments only further emphasize the need for an integrated care approach. Further research should be directed to identifying the specific palliative care needs of patients with HM and their families and developing interventions to address to those.

We would like to thank Leanne Smit, Tobias Wieles, Mathijs Kruizinga, Iris Groeneveld, Lotte van der Stap, and our colleagues at the Center of Expertise Palliative Care of the LUMC.

Conclusions

Patients with HM who visited the ED in the last 3 months of life are more often hospitalized and die in hospital compared to patients with ST. To improve care during the end-of-life trajectory, especially for patients with HM, palliative care should be timely integrated in standard oncological care.

Supplemental Material

Supplemental Material, Appendix_1 - End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach

Supplemental Material, Appendix_1 for End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach by Mary-Joanne Verhoef, Ellen J. M. de Nijs, Claudia S. Ootjers, Marta Fiocco, Anne J. Fogteloo, Christian Heringhaus, Corrie A. M. Marijnen, Nanda Horeweg and Yvette M. van der Linden in American Journal of Hospice and Palliative Medicine®

Footnotes

Authors’ Note

As approved by the Medical Ethics Committee of the LUMC and according to Dutch and European law, informed consent from patients was not necessary because of the retrospective design of this study.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Mary-Joanne Verhoef

Supplemental Material

Supplemental material for this article is available online.

References

McGrath

Holewa

Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care (Engl). 2007;16(2):164–171.

Hui

Didwaniya

Vidal

, et al. Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer. 2014;120(10):1572–1578.

El-Jawahri

Abel

Steensma

, et al. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015;121(16):2840–2848.

Hui

Bansal

Park

, et al. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015;26(7):1440–1446.

Odejide

Salas Coronado

Watts

Wright

Abel

. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014;10(6):e396–403.

Moreno-Alonso

Porta-Sales

Monforte-Royo

Trelis-Navarro

Sureda-Balari

De Sevilla-Ribosa

. Palliative care in patients with haematological neoplasms: an integrative systematic review. Palliat Med. 2018;32(1):79–105.

Hui

Kim

Kwon

, et al. Access to palliative care among patients treated at a comprehensive cancer center. Oncologist. 2012;17(12):1574–1580.

O’Connor

Harris

Ache

Casarett

. Hospice admissions for cancer in the final days of life: independent predictors and implications for quality measures. J Clin Oncol. 2014;32(28):3184–3189.

LeBlanc

El-Jawahri

. When and why should patients with hematologic malignancies see a palliative care specialist? Hematology Am Soc Hematol Educ Program. 2015;2015:471–478.

10.

World Health Organization. WHO Definition of Palliative Care. Cancer. 2018. http://www.who.int/cancer/palliative/definition/en/. Accessed May 10, 2019.

11.

Howell

Shellens

Roman

Garry

Patmore

Howard

. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011;25(6):630–641.

12.

Murray

Kendall

Boyd

Sheikh

. Illness trajectories and palliative care. BMJ. 2005;330(7498):1007–1011.

13.

Temel

Greer

Muzikansky

, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–742.

14.

Bakitas

Lyons

Hegel

, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the project ENABLE II randomized controlled trial. JAMA. 2009;302(7):741–749.

15.

Vanbutsele

Pardon

Van Belle

, et al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol. 2018;19(3):394–404.

16.

El-Jawahri

LeBlanc

VanDusen

, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2016;316(20):2094–2103.

17.

Button

Bolton

Chan

Chambers

Butler

Yates

. A palliative care model and conceptual approach suited to clinical malignant haematology. Palliat Med. 2019;33(5):483–485.

18.

Zimmermann

Palliative care for patients with hematological malignancies: time for a new model. Leuk Res. 2016;48:78–79.

19.

Bruera

Hui

. Conceptual models for integrating palliative care at cancer centers. J Palliat Med. 2012;15(11):1261–1269.

20.

Boyd

Murray

. Recognising and managing key transitions in end of life care. BMJ. 2010;341:c4863.

21.

Grudzen

Stone

Morrison

. The palliative care model for emergency department patients with advanced illness. J Palliat Med. 2011;14(8):945–950.

22.

Howell

Roman

Cox

, et al. Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. BMC Palliat Care. 2010;9:9.

23.

Cheng

Sham

Chan

. Intensive palliative care for patients with hematological cancer dying in hospice: analysis of the level of medical care in the final week of life. Am J Hosp Palliat Care. 2015;32(2):221–225.

24.

Earle

Neville

Landrum

, et al. Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care. 2005;17(6):505–509.

25.

Earle

Park

Lai

Weeks

Ayanian

Block

. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21(6):1133–1138.

26.

Verhoef

de Nijs

Horeweg

, et al. Palliative care needs of advanced cancer patients in the emergency department at the end of life: an observational cohort study. Support Care Can. 2019;28(3):1097–1107. doi:10.1007/s00520-019-04906-x.

27.

Gilbert

Lowenstein

Koziol-McLain

Barta

Steiner

Chart reviews in emergency medicine research: where are the methods?

Ann Emerg Med. 1996;27(3):305–308.

28.

Oken

Creech

Tormey

, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655.

29.

Bruck

Pierzchlewska

Kaluzna-Oleksy

, et al. Dying of hematologic patients—treatment characteristics in a German University hospital. Supp Care Can. 2012;20(11):2895–2902.

30.

Goldwasser

Vinant

Aubry

, et al. Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: a national registry-based study. Cancer. 2018;124(14):3044–3051.

31.

Michael

Beale

O’Callaghan

, et al. Timing of palliative care referral and aggressive cancer care toward the end-of-life in pancreatic cancer: a retrospective, single-center observational study. BMC Palliat Care. 2019;18(1):13.

32.

Prod’homme

Jacquemin

Touzet

Aubry

Daneault

Knoops

. Barriers to end-of-life discussions among hematologists: a qualitative study. Palliat Med. 2018;32(5):1021–1029.

33.

LeBlanc

O’Donnell

Crowley-Matoka

, et al. Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. J Oncol Pract. 2015;11(2):e230–e238.

34.

El-Jawahri

Keenan

Abel

, et al. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016;3(6):e276–283.

35.

Manitta

Philip

Cole-Sinclair

. Palliative care and the hemato-oncological patient: can we live together? A review of the literature. J Palliat Med. 2010;13(8):1021–1025.

36.

LeBlanc

Roeland

El-Jawahri

. Early palliative care for patients with hematologic malignancies: is it really so difficult to achieve? Curr Hematol Malig Rep. 2017;12(4):300–308.

37.

Chung

Lyckholm

Smith

. Palliative care in BMT. Bone Marrow Transplant. 2009;43(4):265–273.

38.

Thomas

Crisp

Campbell

. The importance of quality of life for patients living with myelodysplastic syndromes. Clin J Oncol Nurs. 2012;16(Suppl):47–57.

39.

Hui

Kim

Roquemore

Dev

Chisholm

Bruera

. Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer. 2014;120(11):1743–1749.

40.

Ansell

Howell

Garry

, et al. What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records. Palliat Med. 2007;21(6):487–492.

41.

Bakitas

Tosteson

, et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the enable III randomized controlled trial. J Clin Oncol. 2015;33(13):1438–1445.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB